In A549 human lung adenocarcinoma cells, we found that TNF-a and several commonly used chemotherapeutic agents upregulated the expression of Bcl-x and/or B¯-1/A1 through an NF-kB-dependent pathway. While parental A549 cells were resistant to the cytotoxic eects of both TNF-a and chemotherapy agents, NF-kBblocked A549 cells were sensitized to both. Expression of either Bcl-x or B¯-1/A1 in the NF-kB-de®cient cells at physiological levels provided dierential protection against TNF-a and chemotherapeutic treatment. These studies provide a potential mechanism for the phenomenon of chemotherapy-induced chemoresistance, and also reveal a potential strategy by which chemoresistance can be overcome. Oncogene (2000) 19, 4936 ± 4940.
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Keywords: NF-kB; Bcl-x; B¯-1; chemoresistance; chemosensitization Much insight into cancer biology and treatment strategies has come from studies of tumor necrosis factor alpha (TNF-a) (Smith et al., 1994) , which was initially characterized as a 17 kd soluble serum factor found to mediate tumor regression in certain types of transplanted tumors. The dissection of signaling pathways and structure function studies of TNF receptor I (TNFRI) have revealed that this receptor transduces both proapoptotic and antiapoptotic signals. By the recruitment of death domain containing proteins through interaction with its own death domain, TNFRI is capable of initiating a proteolytic cascade resulting in the activation of pro-death caspases (Hsu et al., 1995 (Hsu et al., , 1996 Ashkenazi and Dixit, 1998; Scadi et al., 1998; Li et al., 1998; Luo et al., 1998) . In addition, TNFRI also activates the NF-kB transcription factor, which provides cell survival signals through the upregulation of target antiapoptotic genes (Beg and Baltimore, 1996; Wang et al., 1996; Van Antwerp et al., 1996; Liu et al., 1997) .
Recently, work from our laboratory, as well as others, have identi®ed NF-kB-regulated genes which mediate cell survival from proapoptotic stimuli (Tamatani et al., 1999; Lee et al., 1999a; Wang et al., 1998 Wang et al., , 1999 Stehlik et al., 1998; Chu et al., 1997; Wu et al., 1998; Zong et al., 1999; Grumont et al., 1999) . Our initial studies focused on CD40, a member of the TNFreceptor superfamily, which plays important roles in humoral immunity as well as in preventing B cells from undergoing apoptosis from a variety of stimuli. Using B lymphocyte cell lines expressing a dominant active IkB construct which inhibited NF-kB signaling, we were able to establish the importance of NF-kB signaling in mediating cell survival signaling upon CD40 activation. We also found that this ability of CD40 to rescue B lymphocytes from cell death required the NF-kB-mediated upregulation of two antiapoptotic members of the Bcl-2 family, namely Bcl-x and B¯-1.
To determine whether TNF receptor activation, like CD40 activation, could also upregulate Bcl-x and B¯-1 expression, Northern blots were performed on RNA samples isolated from A549 cells treated with TNF-a for various lengths of time (Figure 1b) . Similiar to what was observed in B lymphocytes after CD40 activation, TNF receptor engagement led to dramatic upregulation of both Bcl-x and B¯-1 transcripts. The upregulation of both was detectable as early as 1 h post-stimulation, with transcript levels for Bcl-x maintained at later time points up to 8 h, and the levels of B¯-1 starting to decrease by then (data not shown). The blots were also probed against human BAG-1, an antiapoptotic gene that is capable of binding to and enhancing the function of Bcl-2. Unlike Bcl-x and B¯-1, TNF-a treatment did not aect the levels of the BAG-1 transcript, indicating that the upregulation of antiapoptotic genes by TNF-a in A549 cells is not generalized, but speci®c to certain genes.
To determine whether NF-kB activity was required for the upregulation of Bcl-x and B¯-1 by TNF-a signaling, A549 cells with defective NF-kB signaling were created. A549 cells were doubly transfected to create stable cell lines expressing the reverse tet transactivator (rtTA) and a construct encoding a dominant active, non-degradable IkBa mutant protein (with serine to alanine mutations at positions 32 and 36) driven by a tet-responsive promoter. In the presence of 1 mg/ml of doxycycline, one of the clones that was isolated, 42-7-8, showed complete inhibition of NF-kB activity upon stimulation by either TNF-a or IL-1b (data not shown). As shown in Figure 1a , nuclear extracts from 42-7-8 cells stimulated with 50 ng/ml of TNF-a were not capable of binding to the H2 probe, unlike what was observed in the parental A549 cells, indicating that these cells were not capable of upregulating NF-kB activity in response to TNF-a stimulation.
To determine whether the upregulation of the Bcl-2 homologs upon TNF-a stimulation required NF-kB signaling, Northern blots were performed using RNA isolated from both parental A549 cells and the derived 42-7-8 cells after TNF-a stimulation for various lengths of time. As shown in Figure 1b , 42-7-8 cells were no longer capable of mediating upregulation of either Bclx or B¯-1 in response to TNF-a stimulation. These results indicate that TNF-a-mediated upregulation of Bcl-x and B¯-1 in A549 cells requires intact NF-kB signaling. The levels of expression of BAG-1 were not aected in the 42-7-8 cell background, indicating that the regulation of BAG-1 expression is independent of NF-kB activity.
TNFRI activation leads to downstream signaling events that mediate activation of both a proapoptotic signaling pathway through the activation of preformed caspases, and an antiapoptotic pathway through NFkB-mediated target gene upregulation. To determine whether the NF-kB-blocked 42-7-8 cells were dierentially sensitive to TNF-a stimulation relative to the unmodi®ed A549 cells, both cells were treated with 50 ng/ml of TNF-a for 24 h, and the viability of these cells was measured by MTT assay (Figure 2b ). Parental A549 cells were relatively resistant to the eects of TNF-a exposure, with greater than 95% of the cells retaining viability. In contrast, the viability of the 42-7-8 cells was dramatically decreased to less than 20% after TNF-a treatment. To determine whether the decrease in viability was through an apoptotic pathway,¯uorescence-activated cell sorter (FACS) analysis was performed on annexin-FITC and propidium iodide double-stained cells after TNF-a treatment (Figure 2c) . Following exposure to TNF-a, the fraction of dead cells in the A549 population did not change. Neither the annexin-positive/propidium iodide-negative (annexin+/PI7) fraction, which represents cells in early apoptosis, or the annexin+/PI+ fraction, which represents dead cells that have lost membrane integrity, changed appreciably upon TNF-a treatment. In contrast, the fraction of dead cells increased dramatically in the 42-7-8 cells upon exposure to TNF-a. The annexin+/PI7 fraction increased from 2.9 to 19.8%, and the annexin+/PI+ fraction increased from 5.6 to 13.6% after treatment. These results indicate that the decrease in viability in the 42-7-8 cells following TNF-a exposure was through an apoptotic pathway, and that NF-kB signaling through TNF stimulation protects A549 cells from the proapoptotic eects of TNF-a stimulation.
Both Bcl-x and B¯-1 are known to be able to protect cells from various proapoptotic stimuli. To determine whether the upregulation of these TNF-inducible antiapoptotic genes is capable of mediating survival upon TNF-stimulation, stable derivatives of the 42-7-8 cells expressing either exogenous Bcl-x or B¯-1 were created by viral transduction methods, followed by antibiotic selection. The populations of cells that were resistant to puromycin selection were then assessed for expression levels of the Bcl-x protein by Western analysis or the expression levels of the B¯-1 transcript by Northern analysis (Figure 2a) . The levels of expression of the exogenous Bcl-x protein in the 42-7-8 background (this population of cells is hereafter referred to as 42-7-8/Bcl-x) were comparable to those seen in the parental A549 cells after TNF-a stimulation. The expression levels of the exogenous B¯-1 transcript in the 42-7-8 cell background (hereafter referred to as 42-7-8/B¯-1) were also comparable to the levels of endogenous B¯-1 transcript seen in the parental A549 cells after TNF-a stimulation. Thus, the derived cell populations do not overexpress the exogenously introduced antiapoptotic genes.
To test for the ability of these cells to resist TNF-amediated cell death, 42-7-8/Bcl-x cells and 42-7-8/B¯-1 cells were treated with TNF-a; and cell viability and cell death were assessed as before with MTT and annexin/PI staining, respectively. Both the 42-7-8/Bcl-x and the 42-7-8/B¯-1 cell populations retained viability as assessed by MTT assay, with roughly 65% of the 42-7-8/B¯-1 and about 90% of the 42-7-8/Bcl-x cell populations retaining viability (Figure 2b ). FACS analysis for annexin-FITC and propidium iodide staining showed that the dead fraction did not change in either cell line after TNF treatment (Figure 2c) . Thus, TNF-a-mediated upregulation of either Bcl-x or B¯-1 through an NF-kB-dependent pathway is capable of preventing cell death associated with TNF-a stimulation.
To explore the possibility that inhibition of NF-kB signaling would also sensitize A549 cells to chemotherapy-mediated cell death, we compared the ability of three dierent commonly used chemotherapy agents (cisplatin (CDDP), etoposide (VP-16) and adriamycin) to dierentially aect the cell viability of A549, 42-7-8, 42-7-8/Bcl-x and 42-7-8/B¯-1 cell lines after 24 h of exposure to various concentrations of the chemotherapeutic compounds (Figure 3) . In all three treatments, parental A549 cells were resistant to the pro-death eects of chemotherapy agents, as assessed by MTT Figure 1 TNF-a-mediated upregulation of Bcl-x and B¯-1 in A549 cells requires NF-kB signaling. (a) A549 cells and the derived 42-7-8 cells were treated with 50 ng/ml of TNF-a for the indicated times, and nuclear extracts were prepared and analysed for binding activity to the H2 probe using previously published protocols (Lee et al., 1999b) . 42-7-8 cell lines were generated from parental A549 cells by introduction of constructs encoding for the reverse tet-activator and also for the IkB mutant driven by a tetresponsive promoter. (b) A549 and 42-7-8 cells were treated with 50 ng/ml of total TNF-a for the indicated times, and RNA was collected and processed for Northern analysis. Twenty mg of total RNA was loaded per lane. The blots were then probed with human cDNA probes for Bcl-x, B¯-1, BAG-1 and GAPDH assay. In contrast, the NF-kB-defective 42-7-8 cells were extremely sensitive to even low doses of chemotherapy agents. Expression of Bcl-x or B¯-1 at physiologically-induced levels in the 42-7-8 cell background aorded protection against chemotherapymediated death, with Bcl-x protecting more than B¯-1. In the system used by Wang et al. (1999) overexpression of B¯-1 in the NF-kB-blocked HT1080I ®brosarcoma cell line aorded some protection against TNF-a-mediated cell death and complete protection against etoposide-mediated apoptosis.
Interestingly, the sensitivity of the A549 and derivative cell lines to chemotherapy exposure closely mimics the response seen with TNF-a treatment of the respective cell lines (Figures 2 and 3) . The dierential sensitivity of the A549 and 42-7-8 cell lines to TNF-a- Figure 2 Inhibition of NF-kB signaling sensitizes A549 cells to TNF-a-mediated cell death, and these cells can be rescued by expression of either Bcl-x or B¯-1 at physiological levels. (a) Establishing 42-7-8 cell lines expressing Bcl-x or B¯-1 at physiological levels. 42-7-8 cells were virally transduced with a Bcl-x or B¯-1-expressing construct cloned into the pBABEpuro vector using previously published protocols (Lee et al., 1999b) . Stable populations were selected with 2.5 mg/ml of puromycin, and expression levels of the exogenous genes were assessed for Bcl-x by Western analysis and for B¯-1 by Northern analysis. For the analysis of Bcl-x expression, cells were stimulated for 24 h with 50 ng/ml of TNF-a prior to harvesting. Sample loading was normalized by detection of the levels of tubulin protein (Sigma (T5168)) and GAPDH mRNA transcript. (b) Cells were plated onto a 96-well format and treated for 24 h with 50 ng/ml of TNF-a. Ten ml of a 5 mg/ml MTT solution (in PBS) was added to each well and then incubated from 4 ± 6 h at which point purple crystals of incorporated MTT were observed. One hundred and ten ml of 5% formic acid in isopropanol was then added to each well, and the crystals were dissolved by vigorous pipetting. The samples were then measured at OD nm 650 on a plate reader, and the measurements were compared to a standard curve of untreated cells to assay for viability. (c) To assay for apoptosis, annexin-FITC and propidium iodide double staining was performed on the four cell lines after treatment with 50 ng/ml of TNF-a for 24 h. The stained cells were then analysed by FACS analysis with the FL1-H x-axis representing the FITC staining and the FL2-H y-axis representing the propidium iodide staining. The percentage of dead cells represented in the upper right and lower right quadrant is indicated by the numerical value Overcoming NF-kB-mediated chemoresistance of cancer cells Q Cheng et al mediated cell death can be accounted for by the inability of the 42-7-8 cells to upregulate protective antiapoptotic genes such as Bcl-x and B¯-1 in response to TNF stimulation. To explore the possibility that the dierential sensitivity of the two cell lines to chemotherapeutic compounds occurs through a similiar mechanism, Northern blots were analysed, using RNA from A549 and 42-7-8 cells after treatment with TNF-a and chemotherapeutic agents (Figure 4) . In A549 cells, the levels of both Bcl-x and B¯-1 transcripts increased after TNF-a treatment ( Figure  4 , left panel). Etoposide (VP-16) treatment led to upregulated expression of B¯-1 but not Bcl-x in A549 cells. Adriamycin (ADR) treatment of A549 cells causes the upregulated expression of Bcl-x, but has little eect on B¯-1 expression. Cisplatin (CDDP) treatment led to upregulation of both Bclx and B¯-1 transcripts in the A549 cells. Thus, in our studies, we observed the capability of dierent chemotherapeutic compounds to dierentially mediate upregulation of Bcl-x and B¯-1.
TNF-a-mediated upregulation of Bcl-x and B¯-1 required signaling through NF-kB. To determine whether the chemotherapy-mediated upregulation of Bcl-x and/or B¯-1 also required NF-kB signaling, Northern blots were performed on RNA isolated from 42-7-8 cells after stimulation with various proapoptotic stimuli. As before, TNF treatment did not lead to upregulation of either Bcl-x or B¯-1 in the 42-7-8 cells. Interestingly, none of the chemotherapy agents were capable of mediating upregulation of Bcl-x or B¯-1 in the 42-7-8 background, indicating that chemotherapy-mediated upregulation of these survival genes proceeds through an NF-kBdependent pathway. Wang et al. (1999) also reported the NF-kB-dependent upregulation of B¯-1 in response to etoposide treatment of HT080 cells. Interestingly, dierent chemotherapeutic compounds dierentially upregulated the expression of either Bclx or B¯-1 in the same cells (Figure 4 ). This suggests that there are other signaling pathways and transcription factors, besides for NF-kB, which contribute to the upregulation of these antiapoptotic molecules; however intact NF-kB signaling is necessary for the upregulation. The ability of chemotherapeutic agents to upregulate Bcl-x and/or B¯-1 expression through an NF-kBdependent pathway represents a potential mechanism for chemoresistance. Similiar to TNF-a signaling, chemotherapeutic agents also send two divergent and opposing survival and death signals. The proapoptotic signal is sent via dierent mechanisms unique to each individual chemotherapeutic agent. Many, such as cisplatin, adriamycin and etoposide, function by damaging DNA, and the proapoptotic signal may be through a p53-dependent pathway. The antiapoptotic signal, like TNF signaling, is through the upregulation of antiapoptotic genes such as Bcl-x and B¯-1. As in the case of TNF-a signaling, the antiapoptotic signal mitigates the eect of the proapoptotic signal, thereby lessening the overall ability of the chemotherapy agent to kill the target cell. By blocking NF-kB activity, neither TNF nor chemotoxin is capable of upregulating the expression of Bcl-x or B¯-1, and the only signal sent is a proapoptotic one, with the resulting enhancement of cell death. If this strategy is developed, the ability to chemosensitize tumor cells by NF-kB-inhibition will bene®t clinically by allowing for the treatment of otherwise resistant neoplasias. In addition, by allowing for the use of lower amounts of drugs to achieve the same eect, undesirable side eects can be avoided.
